Abstract: Diabetes currently affects more than 400 million people worldwide. This metabolic disorder causes various micro-and macrovascular complications that accelerate atherosclerosis and yet trigger other cardiovascular diseases. The characteristic frame of hyperglycaemia, hyperinsulinaemia and hyperlipidaemia in diabetes increases several inflammatory mediators leading to endothelial dysfunction and pro-atherosclerotic processes. This MiniReview summarizes evidence that antidiabetic drugs have effects beyond lowering glycaemic levels. In experimental studies, antidiabetic drugs reduce the vascular production and release of pro-inflammatory cytokines, the recruitment, infiltration and activation of immune cells and pro-inflammatory mediators, thus decreasing vascular inflammatory responses; they also re-establish vascular redox homeostasis by reducing oxidative stress and balancing the release of vasoconstrictor and vasodilator factors, hence contributing to the improvement of endothelial function. These effects are associated with a reduction in vascular remodelling due to decreased matrix metalloproteinases expression/activity, reduced inflammatory processes and vascular wall fibrosis. In clinical studies, antidiabetic drugs also reduce the production and release of pro-inflammatory, pro-atherosclerotic and pro-oxidative mediators and improve flow-mediated dilatation, indicating beneficial effects on endothelial function. These bonus effects of antidiabetic drugs may delay and/or reduce the installation and development of the atherosclerotic disease, decrease cardiovascular risk and possibly impact mortality risk, life expectancy and quality.
Diabetes Mellitus and Vascular Dysfunction
Diabetes is one of the most prevalent diseases worldwide. In 2017, 425 million people were diagnosed with diabetes, and in just 5 years, this number is expected/estimated to reach 629 million. In the same year, approximately 5 million people died due to diabetes and its complications, and almost 750 billion dollars per year are spent on the treatment of diabetic patients in the world [1] .
Diabetes mellitus (DM), defined as a metabolic disease resulting from defects in insulin secretion, insulin actions or both, is characterized by chronic hyperglycaemia, disturbances in the metabolism of carbohydrates, lipids and proteins. According to the American Diabetes Association (ADA), DM is classified into four clinical classes: type 1 diabetes (T1D), type 2 diabetes (T2D), gestational diabetes and other specific types of diabetes [2] .
Type 2 diabetes represents 90% of the cases and has its highest incidence in obese people over the age of 40 years. T2D is associated with insulin resistance (a condition where cells fail to respond normally to insulin) and with a compensatory hypersecretion of insulin, which precedes the decline in the secretory function of pancreatic islets [2] .
Diabetes mellitus is linked to several acute and chronic complications that increase morbidity and mortality and affect the patient's life quality [3] [4] [5] . The chronic complications of DM are related to functional and structural damage to the blood vessels and are classified into micro-and macrovascular complications.
Microvascular complications are due to damage to small blood vessels as arterioles, capillaries and venules and in diabetic patients are associated with clinical problems such as retinopathy, nephropathy and neuropathy. Macrovascular complications are those resulting from damage to the large vessels as arteries and veins and in diabetes are associated with coronary artery disease, peripheral arterial disease and stroke [6] . Chronic hyperglycaemia, which leads to endothelial dysfunction and exacerbates insulin resistance, can induce both microand macrovascular complications [7, 8] .
Endothelial dysfunction is a hallmark of several cardiovascular and metabolic diseases, including arterial hypertension [9] , coronary artery disease [10] , congestive heart failure [11] , chronic renal failure [12] , atherosclerosis [13] , T1D [14] and T2D [15] . It occurs not only during the course of the diseases but also in their very beginning. Endothelial dysfunction triggers vascular damage-associated processes (presence of pro-inflammatory cytokines and angiogenic regulatory factors, and loss of redox homeostasis, leading to oxidative stress) in arterial hypertension and diabetes [16, 17] . About 90% of diabetic and prediabetic individuals with high risk of the development of coronary atherosclerosis have endothelial dysfunction [18] , which is also a major risk factor for thrombosis and atherosclerosis [19] .
Endothelial dysfunction likely results from endothelial cell injury, which can be triggered by a number of different stimuli, including oxidative stress, turbulent blood flow, high blood pressure, hyperlipidaemia, hyperinsulinaemia and hyperglycaemia, which can all contribute to endothelial cell activation and initiation of inflammatory processes. Hyperglycaemia, for example, increases the auto-oxidation of glucose by increasing the generation of superoxide anion, hydrogen peroxide and hydroxyl radical and decreasing nitric oxide (NO) bioavailability [20] .
Increased lipid peroxidation and NO consumption associated with increased circulating glucose and oxidized fatty acids levels contribute to endothelial damage and yet to higher mitochondrial reactive oxygen species (ROS) generation [21] . Increased mitochondrial ROS generation, in turn, leads to damage of proteins, DNA, RNA and lipids, which can disrupt mitochondrial calcium transit, leading to mitochondrial permeability transition and apoptosis [22] .
Reduced insulin signalling also leads to endothelial dysfunction, by reducing endothelial NO synthase (eNOS) expression, NO production and activation of enzymes that regulate eNOS activity, such as phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and protein kinase B (Akt) [23] , thus accelerating processes involved in the induction of cardiovascular diseases, such as atherosclerosis [24] . Increased circulating free fatty acids -another key feature in patients with DM -also interfere with insulin signalling by impairing PI3K activity [25] and reducing NO release, further contributing to endothelial dysfunction [26] .
In addition to reducing NO bioavailability, diabetes also decreases endothelium-derived hyperpolarization [27, 28] [EDH, previously associated with the availability and actions of endothelium-derived hyperpolarizing factors; EDH(F)] [29] [30] [31] [32] .
Abnormalities in adenosine 3 0 ,5 0 -cyclic monophosphate signalling pathway, including phosphodiesterase 3 [27, 33] , protein kinase A (PKA) activity [34] and increased synthesis of lysophosphatidylcholine [35] , are associated with a reduction in EDH(F)-mediated dilation in retinal arterioles [36] , mesenteric [27] and carotid arteries [37] , thus compromising the function of both the micro-and macrovasculature. It is important to mention that increased EDH(F)-mediated vasodilation in diabetes has also been reported, which is considered a compensatory mechanism in conditions where NO-mediated vasodilation is compromised [38, 39] . In addition to reduced availability of vasodilator factors, increased synthesis of vasoconstrictor substances by the endothelium (EDCFs; endothelium-derived vasoconstrictor factors), such as endothelin-1 (ET-1) [40, 41] , cyclooxygenase (COX)-derived prostanoids [42] [43] [44] [45] and uridine adenosine tetraphosphate [46] , contributes to endothelial dysfunction [47, 48] .
Advanced glycation end products (AGEs) are additional contributors to endothelial dysfunction [49] . Chronic and/or intermittent hyperglycaemia leads to long-term accumulation of glycated biomolecules and AGEs, which represent a heterogeneous group of chemical products that result from a non-enzymatic reaction between reducing sugars and proteins, lipids and nucleic acids. AGEs and the activation of AGEs receptors (RAGE; receptor for AGEs) lead to oxidative stress and proinflammatory signalling [49] . AGEs-induced glycosylation reduces eNOS activity [8] and positively regulates the expression of inflammatory and prothrombotic genes [50] . AGEs also promote low-density lipoprotein oxidation, which is uptaken by monocytes/macrophages leading to the formation of foam cells and the initiation of the atherosclerotic process [51] .
Oxidative stress per se leads to activation of signalling pathways, including mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinases (Erk1/2), p38 MAPK and c-Jun N-terminal kinases (JNK), involved not only in endothelial dysfunction, but also in inflammation, angiogenesis, cellular proliferation, extracellular matrix expansion, apoptosis and vascular remodelling [40, 52, 53] . Increased ROS production enhances nuclear translocation of nuclear factor-kappa B (NFjB) and promotes the transcription of pro-inflammatory genes, such as monocyte chemoattractant protein-1 (MCP-1/CCL2), vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), as well as pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-a) and interleukin-1 beta (IL-1b) [47] . Furthermore, activation of NFjB and JNK signalling pathways contributes to up-regulation of inducible NOS (iNOS) expression, which in turn is involved in insulin resistance and inflammatory processes [54, 55] .
Together, these studies clearly indicate that hyperglycaemiaand hyperlipidaemia-associated events accelerate endothelial dysfunction and lead to increased expression of inflammatory mediators, triggering fibrotic and thrombotic processes ( fig. 1) . These, in turn, contribute to the micro-and macrovascular complications of diabetes as well as to the installation of a pro-atherosclerotic environment ( fig. 2) .
The next section of the review focuses on experimental and clinical studies indicating that antidiabetic drugs, in addition to reducing glucose levels, improve endothelial function, reestablish a state of redox homeostasis and reduce several inflammatory mediators, which may provide protection against atherosclerotic disease. After a very brief introduction to the main mechanisms of action and target tissues that hold up the clinical use of each class of antidiabetic drugs, the mechanisms by which these drugs attenuate endothelial dysfunction-, inflammation-and atherosclerosis-related events and, therefore, may prevent and reduce diabetes-associated macro-and microvascular complications will be discussed.
should be associated with antidiabetic therapy to control glycaemic levels.
Eight classes of antidiabetic drugs [all orally administered antidiabetic drugs with the exception of the mimetic and glucagon-like peptide-1 (GLP-1) analogues, which are administered by subcutaneous injections] are currently commercially available: biguanides (e.g. metformin), meglitinides (e.g. repaglinide), sulphonylureas (e.g. glimepiride), glitazones (e.g. pioglitazone), mimetic and GLP-1 analogues (e.g. exenatide), dipeptidyl peptidase 4 inhibitors (e.g. sitagliptin), sodium-glucose cotransporter 2 (SGLT2) inhibitors (e.g. dapagliflozin) and a-glucosidase inhibitors (e.g. acarbose). In this MiniReview, we address the first seven classes of antidiabetic drugs with the exception of a-glucosidase inhibitors considering that their use has not been approved in many countries. Figure 3 illustrates the main mechanisms of action and target tissues for the antidiabetic therapeutic arsenal.
Biguanides, such as metformin, are the most widely used drugs in T2D treatment [56] . They are transported into hepatocytes via the organic cation transporter-1 disrupting mitochondrial complex I, leading to a decreased energy state. This results in activation of AMP-activated protein kinase (AMPK) via phosphorylation by the upstream kinases liver kinase B1 and Ca 2+ /calmodulin-dependent protein kinase kinase b.
Biguanides decrease lipid/fatty acid synthesis and glucose output and inhibit gluconeogenic gene expression, in addition to antagonizing glucagon signalling. Treatment of diabetic animals with metformin decreases endothelial dysfunction in different vascular beds. Using the Otsuka Long-Evans Tokushima Fatty (OLETF) rat, a T2D animal model, Matsumoto et al. [44] demonstrated that 4 weeks of treatment with metformin normalizes the imbalance between endothelium-derived relaxing factors (EDRFs) and EDCFs in superior mesenteric arteries, reducing prostanoids production and superoxide generation, improving acetylcholine-induced [NO-and EDH(F)-mediated] relaxation and decreasing COX-mediated contraction.
Sena et al. [57] also observed improved endothelium-dependent vasodilation in aortas (conduit artery) from diabetic and obese rats treated with metformin for 4 weeks. The improved endothelial function was associated with decreased generation of superoxide anion and nitrotyrosine accumulation, as well as with decreased vascular expression of CCL2, a chemokine involved in monocyte recruitment [57] . Wang et al. [58] reported that aortas from diabetic ApoE knockout (ApoE À/À ) mice treated with metformin for 4 weeks exhibit reduced mitochondrial fragmentation and superoxide anion release, critical factors in diabetes-induced acceleration of atherosclerosis, as well as improved endothelium-dependent dilation. These effects were associated with lower AMPK-mediated translocation of the dynamin-related protein, a protein involved in mitochondrial fission, and were independent of a reduction in glucose levels [58] .
In addition to improving endothelial function, treatment with metformin also seems to reduce vascular remodelling by decreasing vascular smooth muscle proliferation, migration and inflammation. Lu et al. [59] demonstrated that treatment of rats subjected to high fructose diet and balloon catheter injury with metformin for 4 weeks reduces carotid thickness and the activity of matrix metalloproteinases (MMP), MMP-2 and MMP-9, which are important in vascular expression of pro-inflammatory factors, such as JNK and NF-jB.
Zhou et al. [60] reported that bone marrow-derived macrophages stimulated with AGEs, one of the major inflammatory mediators associated with atherosclerosis progression in diabetes exhibit a polarization change, towards an anti-inflammatory profile, when treated with metformin. In these cells, metformin decreases expression of CD86 (M1 macrophage marker) and increases CD206 (M2 macrophage marker) expression, in addition to reducing IL-10 expression [60] .
In human cells, metformin also seems to have anti-inflammatory effects. Isoda et al. [61] observed that treatment of endothelial and smooth muscle cells, isolated from human saphenous veins and stimulated with IL-1b, with metformin for 6 hr inhibits IL-6 and IL-8 release by decreasing NF-jB nuclear translocation and activation of pro-inflammatory phosphokinases, such as Akt, p38 and Erk.
Beneficial effects of biguanides are also observed in patients. Caballero et al. [62] , in a randomized, placebo-controlled, double-blind study, demonstrated that patients with impaired glucose tolerance (IGT) treated with metformin for 16 weeks exhibit decreased markers of endothelial dysfunction, such as ICAM-1, VCAM-1 and von Willebrand factor (vWF) when compared with the placebo group.
Similarly, Lund et al. [63] in a randomized, double-blind study observed decreased serum levels of endothelial [64] , in a double-blind, placebo-controlled study, observed that patients with atherosclerosis treated with metformin for 12 weeks exhibit decreased plasma concentrations of hs-CRP, IL-6 and TNF-a as well as decreased gene expression of IL-6 and TNF-a in mononuclear cells isolated from the peripheral blood. Moreover, metformin increased cell expression of sirtuin 1, an enzyme that deacetylates proteins that regulate pro-inflammatory genes such as NF-jB [64] . These effects were independent of a decrease in fasting glucose.
Dehkordi et al. [65] also observed, in a randomized, double-blind, controlled clinical trial study, reduced plasma inflammatory markers, such as IL-8, IL-6 and TNF-a, in obese children treated with metformin for 8 weeks, in comparison with children treated with folic acid.
Similarly, Victor et al. [66] , in an open-label study, showed that women with polycystic ovary syndrome (a common endocrine system disorder associated with endothelial dysfunction) treated for 12 weeks with metformin exhibit decreased rolling and adhesion of polymorphonuclear cells and plasma levels of ICAM-1, ELAM-1, IL-6 and ΤΝF-a, markers of atherosclerosis progress, when compared with a control group that did not receive treatment. Metformin-treated patients exhibited only a modest reduction in blood glucose levels [66] .
A recent study, with more than 3000 patients with pre-diabetes that were followed by 14 years, further supports the idea that metformin treatment reduces cardiovascular events. This randomized, clinical trial showed that treatment with metformin reduces coronary artery calcification severity, an index for coronary atherosclerotic burden, and coronary atherosclerosis without interfering with glycated haemoglobin levels. Of importance, these results were observed only in men and not in women [67] . Table 1 summarizes completed and ongoing clinical trials using biguanides in patients with risk factors for atherosclerosis or with atherosclerotic disease.
Meglitinides and sulphonylureas stimulate endogenous insulin secretion by blocking adenosine triphosphate-sensitive potassium channels (K ATP ) on pancreatic b-cells. They bind to the sulphonylurea receptor subunits present on the b-cell plasma membrane or directly to K ATP channels. The inhibition of K ATP channels leads to depolarization of b-cells, the opening of calcium (Ca 2+ ) channels and, consequently, Ca 2+ influx and exocytosis of insulin secretory vesicles [68] . In addition to the hypoglycaemic effect, repaglinide, a meglitinide, also presents vasoactive properties as demonstrated by Kim et al. [69] . Repaglinide induces relaxation of rat aortas via activation of adenylyl cyclase/PKA and guanylyl cyclase/protein kinase G (PKG) signalling pathways and modulation of K + and Ca 2+ channels by endothelium-independent mechanisms [69] . In addition to vasoactive effects, meglitinides and sulphonylureas exhibit antioxidant effects as demonstrated by Chukwunonso et al. [70] . Diabetic rats treated with repaglinide for 14 days exhibit increased serum activity of antioxidant enzymes, such as superoxide dismutase (SOD), glutathione and catalase [70] . Anti-inflammatory effects were reported in human cells. Renier et al. (2000) demonstrated that human endothelial cells (HUVECs) treated with gliclazide, for 1 to 48 hr, display reduced expression of ELAM-1, VCAM-1, ICAM-1, decreased monocyte adhesion and yet lower glycosylated albumin-induced NF-jB activation [71] .
Schmoelzer and Wascher [72] , in a prospective, randomized, observer-blinded, cross-over study with 12 subjects with IGT, reported that only one dose of repaglinide improves flow-mediated dilatation, an effect associated with a significant reduction in plasma glucose after 2 hr of treatment. Table 2 summarizes completed clinical trials using meglitinides and sulphonylureas in patients with risk factors for atherosclerosis or with atherosclerotic disease.
Glitazones primarily activate the peroxisome proliferator-activated receptor (PPAR)-c, a transcription factor predominantly expressed in adipocytes. PPAR-c regulates the expression of genes involved in insulin action, adipocyte differentiation, inflammation and lipid metabolism and improves insulin sensitivity by increasing glucose uptake by the skeletal musculature and by reducing glucose output from the liver [73] .
Matsumoto et al. [43] demonstrated that treatment of streptozotocin-induced diabetic rats with pioglitazone for 4 weeks normalizes aortic endothelial function without altering glucose levels. This effect was associated with suppression of ET-1 production as well as with a reduction in oxidative stress via increased SOD activity and decreased NAD(P)H oxidase activity [43] .
Similarly, and independently of changes in blood glucose, treatment of insulin-resistant rats with pioglitazone for 8 weeks abolishes the increased vascular (aorta) responsiveness to angiotensin II (Ang II) and decreases protein expression of p47 phox (a component of NAD(P)H oxidase) and angiotensin 1 receptor. Pioglitazone also reduces NAD(P)H oxidase activity and nitrotyrosine levels [74] . Likewise, Aliperti et al. [75] demonstrated that rats with erectile dysfunction (induced by cavernous nerve injury) treated with pioglitazone for 14 days exhibit increased intracavernosal pressure/mean arterial pressure (ICP/MAP) ratio, a parameter used to evaluate erectile function, as well as increased expression of eNOS and neuronal NOS (nNOS), enzymes involved in NO production and penile erection.
In relation to oxidative stress, Gumieniczek et al.
[76] observed a decrease in oxidative stress markers, including lipid peroxidation, nitrotyrosine levels and myeloperoxidase activity, in the heart, lung and testis of hyperglycaemic rats treated with pioglitazone for 4 weeks.
Regarding vascular remodelling and inflammation, Behringer et al. [77] demonstrated that treatment of rats with pulmonary hypertension, but without metabolic disturbances, with pioglitazone for 2 weeks decreases pulmonary arterial systolic pressure and reduces fibrotic process, the proliferation of smooth muscle cells and thickness of small pulmonary arteries. Pioglitazone also reduces cardiac remodelling and pulmonary inflammation, as evidenced by decreased macrophages infiltration [77] .
Similarly, Rudnicki et al. [78] demonstrated that treatment of human endothelial cells for 24 hr with three new thiazolidinediones reduces expression of inflammatory markers, including TNF-a, VCAM-1 and ICAM-1. Moreover, all treatments reduce glucose-induced ROS generation and increase NO production, important factors in the homeostasis of endothelial function [78] . In T2D patients, treatment with rosiglitazone for 12 weeks decreases serum levels of proinflammatory cytokines, such as IL-6 and TNF-a [79] .
Stocker et al. [80] , in a randomized trial that compared anti-inflammatory effects of rosiglitazone versus metformin in T2D patients, observed that only patients treated with rosiglitazone exhibit decreased levels of high-sensitivity C-reactive protein (hs-CRP) and regression of carotid artery intima-media thickness (CIMT), independently of decreased glycaemia.
In addition, Stojanovic et al. [81] reported in a meta-analysis study with 812 patients that treatment with different classes CIMT, carotid intima-media thickness; OGTT, oral glucose tolerance test. of thiazolidinediones improves endothelial function, determined by flow-mediated dilatation (FMD). Interestingly, Saremi et al. [82] demonstrated that treatment of pre-diabetic patients for 3 years with pioglitazone delays the onset of atherosclerosis, by reducing the CIMT, independently of changes in hyperglycaemia, insulin resistance or dyslipidaemia. Table 3 summarizes completed and ongoing clinical trials using glitazones in patients with risk factors for atherosclerosis or with atherosclerotic disease.
Glucagon-like peptide-1 (GLP-1) is a hormone produced mainly in the enteroendocrine L cells of the gut and secreted into the blood stream when food containing fat, protein hydrolysate and/or glucose enters the duodenum. GLP-1 acts in bcells increasing glucose-induced insulin secretion while suppressing glucagon secretion by the pancreas [83] . Mimetics and analogues of GLP-1 are used in T2D treatment by exhibiting actions similar to GLP-1 [84] .
Similar to the antidiabetic drugs mentioned above (biguanides, meglitinides, sulphonylureas and glitazones), GLP-1 analogues also improve endothelial function. Li et al. [85] demonstrated that infusion of liraglutide or exendin-4, two GLP-1 receptor agonists, for 12 hr improves cerebral microcirculation after cerebral artery occlusion in diabetic mice. This result was associated with increased levels of Akt and eNOS phosphorylation, as well as reduced ROS generation. The treatment also protects the brain from inflammation and apoptotic damage by reducing the expression of NF-jB, ICAM-1, caspase-3 and Bcl-2-associated X protein/B-cell lymphoma 2 (Bax/BCl-2) ratio, an index of pro-apoptotic events [85] .
Concerning vascular remodelling and inflammation, Kuroki et al. [86] observed that a single administration of exendin-4, 60 min. after cerebral ischaemia, decreases vascular inflammation in hyperglycaemic mice when compared with vehicle and insulin administration. Exendin-4-treated mice also exhibit reduced expression of TNF-a and ionized Ca 2+ -binding adaptor molecule 1, a factor involved in macrophage activation and proliferation of vascular smooth muscle cells (VSMC) and T lymphocytes, as well as decreased MMP-2 and MMP-9 activation and ROS generation [86] . Similarly, Arakawa et al. [87] demonstrated that treatment with exendin-4 for 28 days reduces ICAM-1 expression and monocytes/leucocytes adhesion to the endothelium of aortas from ApoE À/À mice, independently of blood glucose changes.
Exendin-4 also decreases MCP-1, TNF-a and NF-jB expression in peritoneal macrophages. Human monocytes isolated from healthy volunteers treated for 24 hr with exendin-4 display reduced CD11b expression, an integrin involved in leucocyte adhesion and migration in inflammatory responses [87] . Also in human cells, Liu et al. [88] demonstrated that treatment of endothelial cells with liraglutide for 1 hr decreases TNF-a-and high glucose-induced expression of adhesion 
Slows gastric emptying molecules (VCAM-1, ICAM-1) and PAI-1, a pro-fibrotic factor. In addition, liraglutide also reduces the expression of Nurr77, a transcription factor that regulates PAI-1 transcription [88] . Lu et al. [89] observed that treatment with liraglutide for 1 hr decreases chemotaxis, ROS generation, MMP-2 and MMP-9 activities using a human monocyte cell line stimulated with Ang-II. In a clinical study, Koska et al. [90] observed that subjects with T2D treated with exenatide, a GLP-1 receptor agonist, for 11 days exhibit a greater reactive hyperaemia index, measured by peripheral arterial tonometry, as well as greater relaxation of adipose tissue arterioles in comparison with control subjects. This effect, suggestive of improved endothelial function, occurred independently of a reduction in glucose levels. In vitro, endothelial cells treated with exenatide display increased eNOS and Akt phosphorylation and NO production [90] . Table 4 summarizes completed and ongoing clinical trials using GLP-1 receptor agonists in patients with risk factors for atherosclerosis or with atherosclerotic disease.
Dipeptidyl Peptidase-4 (DPP-4), an enzyme that degrades GLP-1, regulates peripheral levels of the peptide. Gliptins, drugs that prevent GLP-1 degradation and increase GLP-1 systemic concentration by inhibiting DPP-4, are used in T2D treatment [84] .
Mason et al. [91] demonstrated that treatment of obese Zucker rats with saxagliptin, a DPP-4 inhibitor, for 8 weeks, increases Ca 2+ ionophore-induced NO production and decreases peroxynitrite generation in aorta and glomerular endothelial cells. Saxagliptin also reduces plasma sCD40 cells, supporting both antioxidant and anti-inflammatory effects [91] .
In addition to the antioxidant effect, Lu et al. [89] observed that sitagliptin treatment for 28 days decreases aortic thickness, MMP-2 and MMP-9 expression/activity, macrophages vascular infiltration and cellular apoptosis in normoglicaemic ApoE À/À mice infused with Ang II, indicating that sitagliptin improves remodelling by reducing vascular inflammation. Also independently of changes in fasting glucose, a reduction in inflammatory mediators in response to treatment for 2 weeks with alogliptin, another DPP-4 inhibitor, was observed in ApoE À/À mice submitted to arterial injury. In this study, alogliptin reduced vascular gene expression of TNF-a, MCP-1, IL-1b and NF-jB and yet decreased vascular leucocyte infiltration and carotid thickness [92] . Clinical studies showed that uncontrolled T2D patients with coronary disease treated for 6 months with sitagliptin, another DPP-4 inhibitor, exhibit greater reactive hyperaemia peripheral arterial tonometry index, considered an indicator of improved endothelial function, in comparison with conventional treatments -antihypertensive, antidiabetic and antiplatelet drugs. Sitagliptin-treated patients also exhibit a greater reactive hyperaemia index (RHI) and reduced hs-CRP levels, a marker of inflammation, compared to the groups on conventional therapy [93] . Table 5 summarizes completed and ongoing clinical trials using DPP-4 inhibitor in patients with risk factors for atherosclerosis.
Inhibitors of SGLT2 (sodium-glucose transporter 2) are the newest drugs in T2D therapeutics. SGLT2 inhibitors increase glucose excretion by inhibiting this cotransporter [94] .
Salim et al. [95] , using a T1D mouse model induced by a single dose of streptozotocin, observed that treatment with ipragliflozin for 3 weeks improves endothelium-dependent vasodilation and Akt and eNOS phosphorylation in the abdominal aorta. This inhibitor also reduced ROS generation, which is associated with decreased urinary excretion of 8-hydroxy-2 0 -deoxyguanosine (8-OHdG), and inflammatory mediators, such as VCAM-1, ICAM-1 and MCP-1 [95] . Similarly, treatment of obese mice with canagliflozin for 8 weeks decreased the expression of pro-inflammatory biomarkers such as Iba1, IL-6 and TNF-a in neural tissues, as well as macrophages infiltration in the skeletal muscle [96] . In addition to a reduction in glucose levels and insulin resistance, Han et al. [97] observed that treatment with empagliflozin for 8 weeks reduces circulating pro-inflammatory markers such as hs-CRP, TNF-a, IL-6 and MCP-1 in ApoE À/À mice fed a Western diet. The reduction in inflammatory markers was significantly correlated with a decrease in atherosclerotic plaque areas in the aortic arch/valve [97] . Similarly, Leng et al. [98] observed that ApoE À/À mice treated for 12 weeks with dapagliflozin exhibit less vascular inflammation due to reduced plasma concentrations and vascular expression of the inflammasome components, such as nucleotide-binding oligomerization domain-like receptor 3 (NLRP3), IL-1b and IL-18. Dapagliflozin also reduces aortic macrophages infiltration and ROS generation and favours atherosclerotic plaque stabilization. In vitro, dapagliflozin reduces inflammasome activation and decreases IL-1b release in bone marrow-derived macrophages stimulated with high concentrations of glucose and lipids [98] . Ishibashi et al. [99] demonstrated that treatment with tofogliflozin, for 4 and 24 hr, reduces ROS generation, MCP-1 expression and cellular apoptosis in proximal tubular cells from human kidneys stimulated with high glucose concentration.
Possibly due to the recent availability of this new class of drugs, we have not found studies addressing their effects on endothelial (dys)function, vascular redox homeostasis and inflammatory-related events in diabetic patients. However, table 6 summarizes ongoing clinical trials in patients with risk factors for atherosclerosis or with atherosclerotic disease.
Antidiabetic Drugs and Cardiovascular Risk: Is it Just a
Matter of Lowering Glucose Levels?
These studies provide evidence that current antidiabetic drugs have beneficial effects on endothelial function, inflammationand atherosclerosis-related processes, which are directly associated with lower cardiovascular risk. These beneficial effects are summarized in table 7.
Considering that cardiovascular diseases are the major cause of deaths worldwide, drugs that reduce the risk and incidence of cardiovascular diseases deserve special attention.
The UK Prospective Diabetes Study showed that 700 overweight T2D patients treated with metformin and followed for 15 years exhibit reduced risk of fatal and non-fatal diabetesrelated endpoints, such as myocardial infarction, angina, heart failure, stroke, renal failure, among others, as well as a reduction of 42% in diabetes-related death and 36% reduction in all-cause mortality [100] . Similarly, Selvin et al. [101] , in a meta-analysis study, reported a reduction in cardiovascular mortality risk associated with myocardial infarction and stroke events in T2D patients treated with metformin for 1 year.
Atherosclerosis-associated mortality was investigated by Roussel et al. [102] in the study of Reduction of Atherothrombosis for Continued Health (REACH). The study followed 19,691 diabetic patients with atherothrombosis treated with metformin for 1 year and showed a consistent reduction in mortality in elderly patients with congestive heart failure history or reduced creatinine clearance [102] .
In addition to reduced mortality, a reduction in the progression of coronary atherosclerosis, carotid intima-media thickening and atherosclerotic plaque inflammation was also demonstrated in prospective studies following T2D patients treated with other types of antidiabetic drugs. Mita et al. [103] , in a recent randomized, open-label, blinded study, reported that T2D patients treated with sitagliptin for 2 years exhibit reduced CIMT and, therefore, attenuated CIMT progression.
Mizoguchi et al. [104] , comparing the effects of two antidiabetic drugs, pioglitazone and glimepiride, reported that only diabetic patients and patients with impaired glucose tolerance treated with pioglitazone for 4 months exhibit decreased atherosclerotic plaque inflammation.
A long and relevant study performed by Kronmal et al. [105] , where diabetic and non-diabetic adults (65 or over 65 years of age) were treated with insulin or different hypoglycaemic agents for 20 years, demonstrated that the antidiabetic treatments are more effective than insulin in reducing general mortality and mortality associated with cardiovascular events.
Similarly, comparing the effects of the novel glucose-lowering drugs dapagliflozin and DPP-4 inhibitors with insulin in more than 37,000 elderly T2D patients, Nystrom et al. [106] reported a significant reduction in total mortality and mortality associated with cardiovascular events.
Therefore, despite a reduction in glucose levels by antidiabetic drugs, their additional or bonus effects -including antioxidant, anti-inflammatory and antiatherosclerotic effectsare crucial to reduce cardiovascular events and to improve patients' life quality and expectancy.
Conclusion
Current drugs used in the treatment of T2D have effects beyond a reduction in glucose levels. Experimental evidence shows that these drugs reduce the generation of superoxide anion and hydrogen peroxide and, therefore, decrease oxidative stress; increase eNOS expression and NO bioavailability; balance the release of EDCFs and EDRFs; and therefore modulate mechanisms that improve endothelial function. These drugs also prevent or decrease vascular remodelling by decreasing cellular recruitment, migration and proliferation, MMP expression/activity and by reducing vascular apoptosis and fibrosis.
They display anti-inflammatory actions by decreasing proinflammatory cytokines, activation of inflammatory platforms, macrophage infiltration and vascular expression of inflammatory markers. In addition, clinical evidence shows that antidiabetic drugs decrease pro-inflammatory, pro-atherosclerotic and pro-oxidative mediators and improve flow-mediated dilatation.
By decreasing endothelial dysfunction-and inflammationrelated processes, these drugs potentially reduce initial steps involved in the induction and progression of atherosclerosis and may reduce risk factors for cardiovascular diseases and associated mortality, improving life quality and expectancy of diabetic patients.
